Gilenia Reduces Relapse Rates In Multiple Sclerosis Therapy: Novartis
Pharmaceutical Business Review ... oral therapy for relapsing forms of multiple sclerosis (MS), reduced annual relapse rates (ARR) by 62% for treatment naive patients compared to placebo. ... Novartis investigational multiple sclerosis therapy Gilenia(R)* (FTY720) shown ... Novartis moves closer to first oral MS treatment New drug may prevent relapse in MS patients |
Gilenia Reduces Relapse Rates In Multiple Sclerosis Therapy: Novartis - Pharmaceutical Business Review
Submitted by Google Search on
Add new comment